The purpose of this transmittal is to provide an update on the billing guidance to DC Medicaid providers regarding the reimbursement process for inpatient cell and gene therapies (CGTs). The Department of Health Care Finance (DHCF) Medicaid program will cover certain inpatient CGT medications for DC Medicaid beneficiaries, when clinically indicated, through Medicaid Fee-for-Service. DHCF has established specific protocols when submitting claims for these high-cost innovative CGTs. CGT coverage is excluded from the DC Health Care Alliance program.